<DOC>
	<DOCNO>NCT00586911</DOCNO>
	<brief_summary>To assess safety efficacy betaine patient NASH marker disease severity liver histology , liver biochemistry , health relate quality life .</brief_summary>
	<brief_title>Betaine Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Betaine</mesh_term>
	<criteria>Adult male female , age 18 70 ( inclusive ) NASH . Abnormal aminotransferase level ( 1.5x normal ) least two occasion less three month apart . Histologic evidence steatohepatitis liver biopsy perform within six month entry . Absence sustain alcohol ingestion ( le 20 g/d woman 30 g/d men ) . Compensated liver disease blood cell count within follow limit : Hb &gt; 12 gr/dl , platelet &gt; 120,000/mm3 , WBC &gt; 3,000/mm3 TSH ( thyroidstimulating hormone ) within normal limit test laboratory . Appropriate exclusion liver disease viral , autoimmune metabolic/hereditary liver disease . If history diabetes , hemoglobin A1C &lt; 10.0 % . Alphafetoprotein normal range ( obtain within previous year ) , great normal , patient require negative ultrasound hepatocellular carcinoma within prior 3 month . Sexually active female patient childbearing potential must practice adequate contraception treatment period 6 month discontinuation therapy . A pregnancy test obtain entry prior initiation treatment must negative . Female patient must breastfeed . Sexually active male patient must practice acceptable method contraception treatment period 6 month discontinuation therapy . Written inform consent participation study . Treatment experimental drug NASH , betaine , ursodeoxycholic acid ( URSO ) , methionine , rosiglitazone , metformin , pioglitazone , vitamin E within 3 month enrollment time preentry liver biopsy . ( Patients diabetes stable medical management six month prior entry anticipate stable program throughout study eligible . Medications may use include insulin , biguanides , thiazolidnediones , metformin , sulfonylurea . Patients hyperlipidemia medical program control lipids change drug treatment precede six month anticipate change year study also eligible . ) Any cause liver disease base patient history biopsy ( applicable ) NASH Evidence decompensated liver disease history presence ascites , bleed varix , spontaneous encephalopathy . Any known preexisting medical condition could interfere patient 's participation completion study significant cardiovascular dysfunction chronic obstructive pulmonary disease require specific therapy Pregnancy breastfeeding . Unwillingness patient and/or partner use contraception treatment . Previous malignant disease ( nonmelanoma skin cancer ) previous two year . Substance abuse , alcohol , I.V . drug inhale drug . Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate complete protocol . Lactose intolerant patient since placebo preparation contain lactose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>Betaine</keyword>
</DOC>